Supplementary Table 6. Shift in BMI category\* (OL SAS)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| BMI category | **TAF-TAF (*n* = 212)** | | | | **TDF-TAF (*n* = 99)** | | | |
| Baseline | | | | Baseline | | | |
| Underweight (*n* = 12) | Normal  (*n* = 117) | Overweight  (*n* = 77) | Obese  (*n* = 6) | Underweight  (*n* = 2) | Normal  (*n* = 62) | Overweight  (*n* = 33) | Obese  (*n* = 2) |
| Week 144, *n* (%) | | | | | | | | |
| Underweight | 6 (50.0) | 1 (0.9) | 0 | 0 | 2 (100.0) | 1 (1.6) | 0 | 0 |
| Normal | 6 (50.0) | 108 (92.3) | 15 (19.5) | 0 | 0 | 59 (95.2) | 5 (15.2) | 0 |
| Overweight | 0 | 8 (6.8) | 61 (79.2) | 1 (16.7) | 0 | 2 (3.2) | 28 (84.8) | 1 (50.0) |
| Obese | 0 | 0 | 1 (1.3) | 5 (83.3) | 0 | 0 | 0 | 1 (50.0) |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 240, *n* (%) | | | | | | | | |
| Underweight | 5 (45.5) | 2 (1.8) | 0 | 0 | 2 (100.0) | 1 (1.7) | 0 | 0 |
| Normal | 6 (54.5) | 97 (89.0) | 17 (22.7%) | 0 | 0 | 49 (81.7) | 3 (9.1) | 0 |
| Overweight | 0 | 10 (9.2) | 55 (73.3) | 3 (50.0) | 0 | 10 (16.7) | 29 (87.9) | 1 (50.0) |
| Obese | 0 | 0 | 3 (4.0) | 3 (50.0) | 0 | 0 | 1 (3.0) | 1 (50.0) |
| Missing | 1 | 8 | 2 | 0 | 0 | 2 | 0 | 0 |

\*Defined by BMI, Underweight: < 18.5 kg/m2; Normal: ≥ 18.5 to < 25.0 kg/m2; Overweight: ≥ 25.0 to < 30.0 kg/m2; Obese: ≥ 30.0 kg/m2. BMI, body mass index; OL SAS, open-label safety analysis set; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.